TNFRSF17 and Miyoshi myopathy: In addition, upregulation (on PB/PC2 and PC6) and downregulation (on PC4/5 subsets) of CD289 (TLR9) (47) expression and CD269 (B cell maturation antigen, also known as BCMA or TNFRSF17) (48) (on PC2 of SMM and active MM stages) were noted.